Brief: Matinas Biopharma Reports Q2 Loss Per Share $0.03
10/08/2020 22:36
Aug 10 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA REPORTS SECOND QUARTER 2020 FINANCIAL
RESULTS
AND OPERATIONAL HIGHLIGHTS
* Q2 LOSS PER SHARE $0.03
* Q2 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
* MATINAS BIOPHARMA HOLDINGS- ENHANCE-IT STUDY OF MAT9001
AGAINST
VASCEPA EXPECTED TO BE FULLY ENROLLED IN AUG 2020; TOPLINE DATA
ANTICIPATED Q1 2021
* MATINAS BIOPHARMA HOLDINGS - ENACT STUDY OF MAT2203 IN
CRYPTOCOCCAL MENINGITIS RESUMED ENROLLMENT; ON TRACK FOR
POTENTIAL COHORT PROGRESSION Q4 2020
Source text for Eikon: ID:nGNX3sfFny
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing